773b41d4-8c43-4777-99b8-190c7e7793e0
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
- COAGULATION+0.300
- MYOGENESIS+0.300
- APICAL_JUNCTION+0.200
- ESTROGEN_RESPONSE_EARLY+0.200
- ESTROGEN_RESPONSE_LATE+0.200
- HEDGEHOG_SIGNALING+0.200
- IL6_JAK_STAT3_SIGNALING+0.200
- KRAS_SIGNALING_UP+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- E2F_TARGETS-0.500
- G2M_CHECKPOINT-0.400
- INTERFERON_GAMMA_RESPONSE-0.400
- MITOTIC_SPINDLE-0.400
- PROTEIN_SECRETION-0.300
- DNA_REPAIR-0.200
- PEROXISOME-0.200
- PI3K_AKT_MTOR_SIGNALING-0.200
- APOPTOSIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A2-A0CP-01A-11R-A034-07 | — | A | 0.793 |
| 2 | TCGA-AN-A0FT-01A-11R-A034-07 | — | B | 0.790 |
| 3 | TCGA-XF-A9SU-01A-31R-A39I-07 | — | — | 0.781 |
| 4 | SRR5088843 | — | — | 0.778 |
| 5 | 09f758e5-6be1-4f29-ac92-869d92f8fbcf | — | — | 0.772 |
| 6 | TCGA-56-8622-01A-11R-2403-07 | — | cohortSQ1 | 0.762 |
| 7 | TCGA-B6-A40B-01A-11R-A239-07 | — | B | 0.760 |
| 8 | MNG589 | — | — | 0.752 |
| 9 | TCGA-OL-A5D6-01A-21R-A27Q-07 | — | F | 0.748 |
| 10 | TCGA-55-A48Y-01A-11R-A24H-07 | — | cohortA4 | 0.748 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.500 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.100 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |